{
    "clinical_study": {
        "@rank": "46900", 
        "arm_group": {
            "arm_group_label": "Adalimumab", 
            "description": "Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab."
        }, 
        "brief_summary": {
            "textblock": "A multicenter registry to explore the clinical outcome of Chinese adult patients with active\n      Ankylosing Spondylitis *AS* treated with adalimumab,prescribed according to the local\n      label,in the real world practice"
        }, 
        "brief_title": "A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spondylitis, Ankylosing", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "This registry will be conducted in a non-interventional setting for AS patients using\n      adalimumab in China.The primary objective is to evaluate the effectiveness and safety of\n      adalimumab in Chinese AS patients in real world clinical practice.The secondary objective is\n      to 1)compare the clinical outcome in patients with or without good persistence with\n      adalimumab;2)investigate the predicting factors of a good clinical response after\n      discontinuation of adalimumab."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult patients with established diagnosis of ankylosing spondylitis.\n\n          2. Patients eligible to use adalimumab according to the local label without any\n             contraindication.(According to the local label, patients should be screened for\n             active infection,TB,HBV,malignancy and CHF before the prescription of\n             adalimumab,patients with latent TB should start a full course of anti-TB therapy\n             before the use of adalimumab.)\n\n        Exclusion Criteria:\n\n        1.Patients with contraindication or are not appropriate to use adalimumab according to the\n        local label will be excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with a diagnosis of ankylosing spondylitis(any disease duration) who meet\n        the requirements per the local label for treatment with adalimumab."
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901627", 
            "org_study_id": "IMM-12-0115"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Spondylitis, Ankylosing", 
            "adalimumab", 
            "Prospective Studies"
        ], 
        "lastchanged_date": "July 12, 2013", 
        "location": {
            "contact": {
                "email": "jinmei.su <jinmei.su@cstar.org.cn>", 
                "last_name": "Jinmei Su, MD", 
                "phone": "86-10-69158798"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100730"
                }, 
                "name": "Peking Union Medical College Hospital"
            }, 
            "investigator": {
                "last_name": "Xiaofeng Zeng, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter Registry to Evaluate the Clinical Outcome of Chinese Adult Patients With Active Ankylosing Spondylitis Treated With Adalimumab in the Real World Practice", 
        "overall_contact": {
            "email": "jinmei.su <jinmei.su@cstar.org.cn>", 
            "last_name": "Jinmei Su, MD"
        }, 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Xiaofeng Zeng, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Effectiveness of adalimumab, measured as percentage of patients achieving Bath Ankylosing Spondylitis Disease Activity Index *BASDAI* 50 at week12 with adalimumab treatment.", 
            "safety_issue": "No", 
            "time_frame": "week12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Effectiveness of adalimumab measured as change in BASDAI,Ankylosing Spondylitis Disease Activity Scores *ASDAS*,Visual Analogue Scale *VAS* in pain,Patient Global Assessment *PtGA* with adalimumab treatment.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Proportion of patients who achieve each of the ASDAS disease state categories(inactive,mild,moderate,high) with adalimumab treatment.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "description": "Physician Global Assessment*PGA*. Inflammatory Bowel Disease *IBD*", 
                "measure": "Improvement of extra-articular manifestation with adalimumab treatment compared to baseline: uveitis flare rates, patient proportion with VAS scale at 1 in IBD PtGA, patient proportion with skin lesion clear or almost clear in psoriasis PGA.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "BASDAI50 response rate at week 26 and week52 in patients still on adalimumab compared to patients who discontinued adalimumab early.", 
                "safety_issue": "No", 
                "time_frame": "week26 and 52"
            }, 
            {
                "measure": "Change in BASDAI, ASDAS, and VAS in pain and PtGA in patients still on adalimumab compared to patients who discontinued adalimumab early.", 
                "safety_issue": "No", 
                "time_frame": "week 26 and 52"
            }, 
            {
                "measure": "Factors influencing the clinical response evaluated by the relapse rate(defined as BASDAI\u22654) after discontinuation of adalimumab in patients who achieved BASDAI <4 and do not restart biologics in the follow-up", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}